Evidence map›Paper›PMID 38996520›Full record

ArticleESMO open2024

Vascular fingerprint tool to identify patients with testicular cancer treated with cisplatin-based chemotherapy at high risk of early cardiovascular events.

A T Meuleman, E L D Volders, S Lubberts, J M Kerst, A N M Wymenga, M J B Aarts, M B Goncalves, J D Lefrandt, G Steursma, J Meijer and 2 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

A T MeulemanDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen.
E L D VoldersDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen.
S LubbertsDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen.
J M KerstDepartment of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam.
A N M WymengaDepartment of Medical Oncology, Medical Spectrum Twente, Enschede.
M J B AartsDepartment of Medical Oncology, Maastricht University Medical Center, GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands.
M B GoncalvesDepartment of Medical Oncology, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisboa, Portugal.
J D LefrandtDepartment of Vascular Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
G SteursmaDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen.
J MeijerDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen.
J NuverDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen.
J A GietemaDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen. Electronic address: j.a.gietema@umcg.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with testicular cancer treated with chemotherapy have an increased risk of developing early cardiovascular events. Identification of patients with testicular cancer at a high risk of these events enables the development of preventative strategies. This study validates the vascular fingerprint tool to identify these patients. PATIENTS AND

methodsWe carried out a multicenter prospective study in patients with metastatic testicular cancer [International Germ Cell Cancer Collaborative Group (IGCCCG) good or intermediate risk; retroperitoneal mass <5 cm]. In eligible patients, the vascular fingerprint was assessed before the start of cisplatin-based chemotherapy, which consists of five risk factors, namely, smoking, overweight (body mass index >25 kg/m

resultsA total of 196 patients with metastatic testicular cancer were included; 15 patients (8%) developed a cardiovascular event: 4 (2%) arterial events and 11 (6%) venous thrombotic events. Overall, 189 vascular fingerprint scores were available. Patients with a high-risk vascular fingerprint (62/189) had a higher risk of developing a cardiovascular event (hazard ratio 3.27, 95% confidence interval 1.16-9.18; log-rank: P = 0.017). Histological diagnosis, prognosis group, cumulative chemotherapy dose, and retroperitoneal mass size did not differ between patients with or without a cardiovascular event. All patients with an arterial event had a high-risk vascular fingerprint compared with 5/11 patients with a venous event. Overweight was more prevalent in patients with cardiovascular events (87% versus 59%; P = 0.037).

conclusionsThe vascular fingerprint is a validated tool to identify patients with testicular cancer at a high risk of developing early cardiovascular events. This tool can be used to develop preventative strategies with anticoagulant treatment.

Indexed as

Cardiovascular DiseasesCisplatinTesticular NeoplasmsAdultAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleMiddle AgedProspective StudiesRisk AssessmentRisk FactorsAntineoplastic AgentsCisplatincardiovascular eventpatients with testicular cancervascular fingerprint

Identifiers

PMID38996520
PMCPMC11298865

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.